Table 2.
All (n = 66) | Weight gain (n = 23) | Weight loss (n = 43) | P value | |
---|---|---|---|---|
Age (years) | 50.0 (26–75)1 | 44.4 ± 2.0 | 53.0 ± 1.5 | 0.0013 |
Race | ||||
African–American | 28 (42%) | 5 (22%) | 23 (53%) | 0.022 |
Hispanic | 19 (29%) | 10 (43%) | 9 (21%) | 0.083 |
White | 16 (24%) | 6 (26%) | 10 (23%) | |
Other | 3 (5%) | 2 (9%) | 1 (2%) | |
Initial BMI (kg/m2) | 31.7 (18.6–70)1 | 30.4 ± 7.1 | 32.4 ± 10.6 | 0.4 |
Cancer type | ||||
IDC | 64 (97%) | 22 (96%) | 42 (98%) | |
Poorly differentiated | 2 (3%) | 1 (4%) | 1 (2%) | |
Initial tumor size (cm) | 5.6 (0–21) | 4.9 ± 4.2 | 6.0 ± 4.0 | 0.25 |
Initial Ki-67 | 74.5 (4–100)1 | 72.9 ± 20.1 | 75.4 ± 23.7 | 0.66 |
Chemotherapy | ||||
TAC | 54 (82%) | 18 (78%) | 36 (84%) | 0.35 |
Platinum-based | 10 (15%) | 4 (17%) | 6 (14%) | |
Other | 2 (3%) | 1 (4%) | 1 (2%) | |
Breast surgery | ||||
TM | 31 (47%) | 11 (48%) | 20 (47%) | 1.0 |
PM | 34 (52%) | 12 (52%) | 22 (51%) | |
None | 1 (1.5%) | 1 (2%) | ||
Axillary surgery | ||||
SLNB | 20 (30%) | 7 (30%) | 13 (30%) | 1.0 |
ALND | 41 (62%) | 15 (65%) | 26 (60%) | |
SLNB→ALND | 4 (6%) | 1 (4%) | 3 (7%) | |
None | 1 (1.5%) | 1 (2%) |
IDC, invasive ductal carcinoma; TAC, taxane, adriamycin, cyclophosphamide; TM, total mastectomy; PM, partial mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
Mean (range).
African–American versus all.
Hispanic versus all.